This trial is active, not recruiting.

Condition advanced hormone dependent prostate cancer
Treatment firmagon® (degarelix)
Sponsor Ferring Pharmaceuticals
Start date March 2013
End date August 2018
Trial size 103 participants
Trial identifier NCT01861236, 000036


Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Advanced Prostate Cancer that receive Firmagon therapy in the context of usual clinical practice
firmagon® (degarelix)
Monthly subcutaneous injections

Primary Outcomes

Progression-free survival (PFS) failure rate (with failure defined as either prostate-specific antigen (PSA) failure, introduction of additional therapy related to prostate cancer, or death)
time frame: During 3 years treatment

Eligibility Criteria

Male participants from 18 years up to 100 years old.

Inclusion Criteria: - Advanced Prostate Cancer patients to be treated with Firmagon in the context of usual clinical practice - Written informed consent Exclusion Criteria: - Contraindications to Firmagon - Patients already on Firmagon therapy

Additional Information

Official title Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Ferring Pharmaceuticals.